Who are Tislelizumab+Oxaliplatin+Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tislelizumab + cisplatin + paclitaxel, PD-1 combined with chemotherapy, Lenvatinib, tislelizumab, gemcitabine and cisplatin, PD-1 Inhibitor + Chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tislelizumab-oxaliplatin-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tislelizumab+Oxaliplatin+Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tislelizumab+Oxaliplatin+Capecitabine (Tislelizumab+Oxaliplatin+Capecitabine) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor + chemotherapy combination. Area: Oncology.

phase 3 PD-1 inhibitor + chemotherapy combination PD-1 (programmed death receptor 1); DNA (oxaliplatin); thymidylate synthase (capecitabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tislelizumab+Oxaliplatin+Capecitabine (Tislelizumab+Oxaliplatin+Capecitabine) — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. This combination uses a PD-1 inhibitor to enhance immune response against cancer cells while chemotherapy agents directly kill rapidly dividing cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tislelizumab+Oxaliplatin+Capecitabine TARGET	Tislelizumab+Oxaliplatin+Capecitabine	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	phase 3	PD-1 inhibitor + chemotherapy combination	PD-1 (programmed death receptor 1); DNA (oxaliplatin); thymidylate synthase (capecitabine)
Tislelizumab + cisplatin + paclitaxel	Tislelizumab + cisplatin + paclitaxel	First Affiliated Hospital Xi'an Jiaotong University	marketed	PD-1 inhibitor + chemotherapy combination	PD-1 (tislelizumab); DNA (cisplatin); microtubule (paclitaxel)
PD-1 combined with chemotherapy	PD-1 combined with chemotherapy	Shandong Provincial Hospital	marketed	PD-1 inhibitor + chemotherapy combination	PD-1
Lenvatinib, tislelizumab, gemcitabine and cisplatin	Lenvatinib, tislelizumab, gemcitabine and cisplatin	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination	FGFR, VEGFR, RET (lenvatinib); PD-1 (tislelizumab); DNA (gemcitabine, cisplatin)
PD-1 Inhibitor + Chemotherapy	PD-1 Inhibitor + Chemotherapy	Shenyang Sunshine Pharmaceutical Co., LTD.	phase 3	PD-1 inhibitor + chemotherapy combination	PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor + chemotherapy combination class)

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
First Affiliated Hospital Xi'an Jiaotong University · 1 drug in this class
Shandong Provincial Hospital · 1 drug in this class
Shenyang Sunshine Pharmaceutical Co., LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tislelizumab+Oxaliplatin+Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/tislelizumab-oxaliplatin-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab